基于性别的广泛期小细胞肺癌巩固性胸部放疗差异效应
该分析纳入2014至2021年诊断的IV期小细胞肺癌患者1227例(化疗850例、化免377例),评估巩固性胸部放疗(cTRT)与生存的关系。女性接受cTRT与更优的总生存(HR 0.67;95%CI 0.52-0.87)和无进展生存(HR 0.63;95%CI 0.49-0.82)相关,男性未见OS或PFS获益。作者认为cTRT的生存疗效可能受性别影响,女性患者似乎更可能获益。
要点
- 女性接受cTRT与更优OS相关(HR 0.67;95%CI 0.52-0.87)
- 女性接受cTRT与更优PFS相关(HR 0.63;95%CI 0.49-0.82)
- 男性未见OS或PFS获益(OS HR 1.03;PFS HR 1.12)
核心结论
- cTRT的生存疗效可能受性别影响,女性患者似乎比男性患者更可能获益。
- 这些发现反映的性别生存趋势与CREST试验中观察到的效应量相似。
- 作者认为,在研究广泛期小细胞肺癌cTRT的随机对照试验中应考虑按性别分层。
研究设计与样本
- 基于去标识电子健康记录衍生数据库的回顾性分析,纳入2014至2021年诊断的IV期小细胞肺癌患者。
- 共纳入1227例完成4至6周期一线系统治疗(铂双药化疗或化疗联合免疫治疗)的患者,其中化疗850例、化疗联合免疫治疗377例。
- 采用多变量Cox比例风险回归评估OS和PFS,以是否接受cTRT为自变量并按性别分层;敏感性分析采用接受cTRT的逆概率加权。
主要发现
- 接受与未接受cTRT的患者基线特征无统计学显著差异。
- 女性中,cTRT与更优OS相关(校正HR 0.67;95%CI 0.52-0.87),与更优PFS相关(HR 0.63;95%CI 0.49-0.82)。
- 男性中未观察到cTRT的OS获益(HR 1.03;95%CI 0.80-1.31)或PFS获益(HR 1.12;95%CI 0.85-1.47)。
- 加权分析结果相似。
临床怎么用
- 作者认为,在研究广泛期小细胞肺癌cTRT的随机对照试验中应考虑按性别分层。
局限性
- 作者指出,这种关联的基础尚需阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The landmark randomized trial on chest irradiation in extensive disease small cell lung cancer (CREST) demonstrated that consolidative thoracic radiation therapy (cTRT) improved overall (OS) and progression-free survival (PFS) after initial chemotherapy (chemo) in extensive-stage small cell lung cancer, with potentially increased benefit in women compared with men. It is unknown whether similar findings would apply after chemoimmunotherapy became the standard first-line treatment. In this analysis, we report national practice patterns and survival outcomes of cTRT according to patient sex. METHODS AND MATERIALS: We included patients from de-identified electronic health record-derived database diagnosed with stage IV small cell lung cancer (2014-2021) who completed 4 to 6 cycles of first-line systemic therapy (platinum-doublet chemotherapy or chemoimmunotherapy). We evaluated OS and PFS using multivariable Cox proportional hazards regression with receipt of cTRT as an independent variable and stratified by sex. As a sensitivity analysis, we weighted the models by the inverse probability of receiving cTRT. RESULTS: A total of 1227 patients were included (850 chemotherapy, 377 chemoimmunotherapy). There were no statistically significant differences in baseline characteristics between patients who did and did not receive cTRT. Among women, cTRT was associated with superior OS (adjusted hazard ratio [HR], 0.67; 95% CI, 0.52-0.87) and PFS (HR, 0.63; 95% CI, 0.49-0.82) compared with those not receiving cTRT. Conversely, no OS or PFS benefit with cTRT was observed in men (OS HR, 1.03; 95% CI, 0.80-1.31; PFS HR, 1.12; 95% CI, 0.85-1.47). Findings were similar in weighted analyses. CONCLUSIONS: The survival efficacy of cTRT may be moderated by sex, with female patients appearing more likely to benefit than male patients. These findings reflect sex-based survival trends with similar effect sizes to those observed in the CREST trial. Although the underpinnings of this association need to be elucidated, stratification by sex should be considered for randomized-controlled trials studying cTRT in extensive-stage small cell lung cancer.
引用
- Jairam V, Soulos PR, K C M, et al. Differential Effect of Consolidative Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer Based on Sex. Adv Radiat Oncol. 2023. PMID: 38778819. doi:10.1016/j.adro.2023.101413
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。